Deutsche Bank Ag Trimmed By $1.48 Million Its Unisys (UIS) Holding; Profile of 2 Analysts Covering ZIOPHARM Oncology, Inc. (ZIOP)

Unisys Corporation (NYSE:UIS) Logo

Among 2 analysts covering ZIOPHARM Oncology (NASDAQ:ZIOP), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ZIOPHARM Oncology had 4 analyst reports since November 15, 2018 according to SRatingsIntel. Raymond James upgraded it to “Outperform” rating and $5 target in Thursday, November 15 report. The firm earned “Buy” rating on Wednesday, March 6 by H.C. Wainwright. See ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) latest ratings:

06/03/2019 Broker: H.C. Wainwright Rating: Buy New Target: $5.5 Maintain
06/03/2019 Broker: BidaskScore Rating: Hold Downgrade
26/02/2019 Broker: BidaskScore Rating: Buy Upgrade
15/11/2018 Broker: Raymond James Old Rating: Market Perform New Rating: Outperform New Target: $5 Upgrade

Deutsche Bank Ag decreased Unisys Corp (UIS) stake by 22.62% reported in 2018Q4 SEC filing. Deutsche Bank Ag sold 134,231 shares as Unisys Corp (UIS)’s stock declined 1.48%. The Deutsche Bank Ag holds 459,299 shares with $5.34M value, down from 593,530 last quarter. Unisys Corp now has $681.82 million valuation. The stock increased 0.45% or $0.06 during the last trading session, reaching $13.36. About 1.22M shares traded or 100.39% up from the average. Unisys Corporation (NYSE:UIS) has risen 18.84% since March 15, 2018 and is uptrending. It has outperformed by 14.47% the S&P500. Some Historical UIS News: 16/04/2018 – UNISYS NAMES MATHEW NEWFIELD AS CHIEF INFORMATION SECURITY; 09/05/2018 – UNISYS GETS U.S. CUSTOMS AND BORDER PROTECTION CONTRACT; 02/05/2018 – Wells Fargo Bank NA Exits Position in Unisys; 28/03/2018 – Unisys Announces New Advanced Endpoint Protection Solution to Help Organizations Combat Today’s Rapidly Evolving Malware; 19/03/2018 – UNISYS CORP – AUSTRALIAN DEPARTMENT OF HOME AFFAIRS HAS SIGNED A MULTI-YEAR CONTRACT WITH UNISYS AUSTRALIA TO DESIGN AND IMPLEMENT NEW EBIS SYSTEM; 24/04/2018 – Unisys Closes Above 50-Day Moving Average: Technicals; 25/04/2018 – Hong Kong Bank Customers Ready to Embrace Artificial Intelligence and Automation in Digital Banking – Unisys Banking Insights S; 16/04/2018 – UNISYS’S NEWFIELD FORMERLY DIRECTOR OF MSS FOR IBM; 01/05/2018 – Unisys 1Q Rev $708.4M; 01/05/2018 – Unisys Backs 2018 Rev $2.75B-$2.875B

More notable recent ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) news were published by: which released: “Ziopharm Oncology CEO to Present at the CAR-TCR Summit Europe – GlobeNewswire” on February 21, 2019, also with their article: “Recent Analysis Shows Lattice Semiconductor, ZIOPHARM Oncology, Ferro, SYNNEX, AxoGen, and Twin Disc Market Influences — Renewed Outlook, Key Drivers of Growth – GlobeNewswire” published on February 14, 2019, published: “The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings – Yahoo Finance” on March 05, 2019. More interesting news about ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) were released by: and their article: “Roche takeout of Spark Therapeutics stokes gene therapy players – Seeking Alpha” published on February 25, 2019 as well as‘s news article titled: “Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4 – Nasdaq” with publication date: March 01, 2019.

The stock increased 2.85% or $0.1 during the last trading session, reaching $3.61. About 3.78M shares traded or 103.65% up from the average. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has declined 25.14% since March 15, 2018 and is downtrending. It has underperformed by 29.51% the S&P500. Some Historical ZIOP News: 10/05/2018 – ZIOPHARM 1Q LOSS/SHR 15C, EST. LOSS/SHR 13C; 22/04/2018 – DJ ZIOPHARM Oncology Inc, Inst Holders, 1Q 2018 (ZIOP); 16/05/2018 – Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 in Breast Cancer and Glioblastoma at American Socie; 10/05/2018 – Ziopharm 1Q Loss/Shr 15c; 10/05/2018 – Ziopharm Says Focusing Resources on Studies of Controlled IL-12 in Additional Tumor Types; 17/05/2018 – Ziopharm Presenting at Conference Jun 4; 16/05/2018 – Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting; 05/03/2018 Ziopharm Closes Above 50-Day Moving Average: Technicals; 09/03/2018 – New Research Coverage Highlights Great Western, Acadia Realty Trust, lnterpace Diagnostics Group, Abercrombie & Fitch, United Rentals, and ZIOPHARM Oncology — Consolidated Revenues, Company Growth, and Expectations for 2018; 10/05/2018 – Ziopharm at American Society of Clinical Oncology Meeting Jun 4

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company has market cap of $583.42 million. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to IntrexonÂ’s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma . It has a 3.78 P/E ratio. The Company’s synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

More notable recent Unisys Corporation (NYSE:UIS) news were published by: which released: “3 Top Tech Stocks to Buy in February – Motley Fool” on February 21, 2019, also with their article: “Unisys Named a Leader in Gartner 2019 Magic Quadrant for Managed Workplace Services, North America; Company Positioned Highest on Ability to Execute Axis – PRNewswire” published on March 12, 2019, published: “Unisys to Present at IATA World Cargo Symposium on Importance of Real-Time Data for a Truly Connected Cargo Supply Chain – PRNewswire” on March 11, 2019. More interesting news about Unisys Corporation (NYSE:UIS) were released by: and their article: “58 Biggest Movers From Yesterday – Benzinga” published on February 14, 2019 as well as‘s news article titled: “Unisys Announces Availability of Unisys Stealth® 4.0 Security Software, the First Product with Dynamic Isolationâ„¢ Capabilities to Quickly Isolate Users and Devices at the First Sign of Trouble – PRNewswire” with publication date: March 05, 2019.

Analysts await Unisys Corporation (NYSE:UIS) to report earnings on May, 7. They expect $0.35 EPS, up 84.21% or $0.16 from last year’s $0.19 per share. UIS’s profit will be $17.86 million for 9.54 P/E if the $0.35 EPS becomes a reality. After $0.97 actual EPS reported by Unisys Corporation for the previous quarter, Wall Street now forecasts -63.92% negative EPS growth.

Investors sentiment decreased to 1.29 in Q4 2018. Its down 0.29, from 1.58 in 2018Q3. It fall, as 30 investors sold UIS shares while 52 reduced holdings. 48 funds opened positions while 58 raised stakes. 60.94 million shares or 1.27% more from 60.18 million shares in 2018Q3 were reported. Balyasny Asset Mngmt Limited accumulated 35,100 shares or 0% of the stock. Louisiana State Employees Retirement Systems stated it has 19,177 shares or 0.01% of all its holdings. Pnc Fincl Serv Group Inc reported 1,177 shares. Brandywine Glob Inv Lc reported 0% stake. Commonwealth Of Pennsylvania School Empls Retrmt has invested 0% of its portfolio in Unisys Corporation (NYSE:UIS). Walleye Trading Limited Company invested 0.01% in Unisys Corporation (NYSE:UIS). The New York-based Indexiq Limited Company has invested 0.06% in Unisys Corporation (NYSE:UIS). Cubist Systematic Strategies Lc holds 0.01% or 22,712 shares. Diligent Ltd Llc stated it has 13,544 shares or 0.1% of all its holdings. Hsbc Plc reported 54,428 shares stake. Bnp Paribas Arbitrage has 0% invested in Unisys Corporation (NYSE:UIS) for 10,006 shares. D E Shaw & Inc accumulated 1.11M shares. Minnesota-based Us Financial Bank De has invested 0% in Unisys Corporation (NYSE:UIS). 585,413 are held by Charles Schwab Inc. Acadian Asset Limited Com, Massachusetts-based fund reported 300,990 shares.

Deutsche Bank Ag increased Investors Bancorp Inc New (NASDAQ:ISBC) stake by 876,463 shares to 2.22M valued at $23.09M in 2018Q4. It also upped Grupo Financiero Galicia S A (NASDAQ:GGAL) stake by 184,124 shares and now owns 536,439 shares. American Renal Associates Ho was raised too.

Unisys Corporation (NYSE:UIS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.